Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

Kirjoittajat

  • Salman Tahir Shafi Sharif Medical and Dental College, Lahore

DOI:

https://doi.org/10.53778/pjkd40353

Avainsanat:

Rejection, kidney transplant, acute rejection, chronic rejection, antibody mediated rejection, complement,, plasmapheresis, Bortezomib,, Rituximab, Eculizumab, Tocilizumab

Abstrakti

Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.

PJKD

Tiedostolataukset

Julkaistu

2021-01-31

Numero

Vol 4 Nro 03 (2020): Pakistan Journal of Kidney Diseases

Osasto

Review Article

Lisenssi

Copyright (c) 2021 Salman Tahir Shafi

Creative Commons License

Tämä työ on lisensoitu Creative Commons Nimeä-EiKaupallinen 4.0 Kansainvälinen Julkinen -lisenssillä.

Viittaaminen

Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353